NFE2L2 and ovarian carcinoma: Manandhar et al. revealed that Nrf2 inhibition represses HER2 signaling in ovarian carcinoma cells, suggesting that Nrf2 modulation might be a therapeutic strategy to limit tumor growth in ovarian cancers [26].